Publication
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (10)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 10
- cancerCutaneous Melanomacivic_curation1.00
- cancerMelanomacivic_curation1.00
- drugPembrolizumabcivic_curation1.00
- geneB2Mcivic_curation1.00
- geneJAK1civic_curation1.00
- geneJAK2civic_curation1.00
- variantB2M S14FScivic_curation1.00
- variantJAK1 Q503*civic_curation1.00
- variantJAK2 c.1641+1dupcivic_curation1.00
- variantJAK2 Splice Site (c.1641+2T>G)civic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27433843
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| B2M S14FS1 | ||||||||
| Pembrolizumab | Cutaneous MelanomaALIAS | Predictive | C | Supports Resistance | 3 | accepted | EID1569Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies… (full text at CIViC) PMID 27433843 · Zaretsky et al., 2016 · Open in CIViC | civic |
| JAK1 Q503*1 | ||||||||
| Pembrolizumab | Cutaneous MelanomaALIAS | Predictive | C | Supports Resistance | 4 | accepted | EID1567Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies… (full text at CIViC) PMID 27433843 · Zaretsky et al., 2016 · Open in CIViC | civic |
| JAK2 c.1641+1dup1 | ||||||||
| Pembrolizumab | Cutaneous MelanomaALIAS | Predictive | C | Supports Resistance | 4 | accepted | EID1568Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies… (full text at CIViC) PMID 27433843 · Zaretsky et al., 2016 · Open in CIViC | civic |
| JAK2 Splice Site (c.1641+2T>G)1 | ||||||||
| Pembrolizumab | Melanoma | Predictive | C | Supports Resistance | 3 | accepted | EID4825In a retrospective study of four relapsed, malignant melanoma patients, JAK2 (c.1641+2T>G) F547 splice site mutation was associated with acquired resistance to pembrolizumab monotherapy in one patient… (full text at CIViC) PMID 27433843 · Zaretsky et al., 2016 · Open in CIViC | civic |